UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.957-969

2021

Volltextzugriff (PDF)

We can do better: a fresh look at echinocandin dosing

Journal of antimicrobial chemotherapy, 2018-01, Vol.73 (suppl_1), p.i44-i50

2018

Volltextzugriff (PDF)

Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma

Cancer chemotherapy and pharmacology, 2021-07, Vol.88 (1), p.69-79

2021

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0221321-e0221321

2023

Volltextzugriff (PDF)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Antimicrobial agents and chemotherapy, 2018-06, Vol.62 (6)

2018

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae

Antimicrobial agents and chemotherapy, 2019-03, Vol.63 (3)

2019

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

Journal of antimicrobial chemotherapy, 2019-04, Vol.74 (Supplement_3), p.iii35-iii41

2019

Volltextzugriff (PDF)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Antimicrobial agents and chemotherapy, 2017-11, Vol.61 (11)

2017

Volltextzugriff (PDF)

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs

Current opinion in pharmacology, 2017-10, Vol.36, p.139-145

2017

Volltextzugriff (PDF)

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

We can do better: a fresh look at echinocandin dosing

Journal of antimicrobial chemotherapy, 2018-03, Vol.73 (3), p.831-831

2018

Volltextzugriff (PDF)

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.161-177

2017

Volltextzugriff (PDF)

Time for Precision: A World Without Susceptibility Breakpoints

Open forum infectious diseases, 2018-12, Vol.5 (12), p.ofy282-ofy282

2018

Volltextzugriff (PDF)

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Journal of pharmacokinetics and pharmacodynamics, 2018-04, Vol.45 (2), p.351-351

2018

Volltextzugriff (PDF)

2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S426-S426

2018

Volltextzugriff (PDF)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S409-S410

2018

Volltextzugriff (PDF)

Traditional PK-PD Indices for Efficacy – Can We Do Better?

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S298-S298

2017

Volltextzugriff (PDF)

Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S298-S298

2017

Volltextzugriff (PDF)

Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S26-S27

2017

Volltextzugriff (PDF)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S298-S298

2017

Volltextzugriff (PDF)

Vancomycin Prescribing Habits – Are We Still Afraid of Mississippi Mud?

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S294-S294

2017

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(44)
Buchkapitel
(2)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Humans
(14)
Pharmacology & Pharmacy
(14)
Microbiology
(10)
Female
(9)
Male
(7)
Abstracts
(5)
Pharmacology
(5)
Aged
(4)
Animals
(4)
Infectious Diseases
(4)
Microbial Sensitivity Tests
(4)
Middle Aged
(4)
Pharmacology/toxicology
(4)
Antifungal Agents - Pharmacokinetics
(3)
Disease Models, Animal
(3)
Echinocandins - Pharmacokinetics
(3)
General & Internal Medicine
(3)
Liver
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export

We can do better: a fresh look at echinocandin dosing

Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity

We can do better: a fresh look at echinocandin dosing

PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

Time for Precision: A World Without Susceptibility Breakpoints

Correction to: PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside

2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S. pneumoniae (SPN)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

Traditional PK-PD Indices for Efficacy – Can We Do Better?

Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species

Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia

Vancomycin Prescribing Habits – Are We Still Afraid of Mississippi Mud?

Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)

Suchergebnisse filtern